Pivotal bioVenture Partners Fund I, L.P. - 07 Nov 2025 Form 4 Insider Report for Evommune, Inc.

Role: Director, 10%+ Owner
Signature: /s/ Robert Hopfner - for Pivotal bioVenture Partners Fund I, L.P., By: Robert Hopfner, Managing Partner
Issuer symbol: EVMN on NYSE
Transactions as of: 07 Nov 2025
Net transactions value: $0
Form type: 4
Filing time: 12 Nov 2025, 16:46:56 UTC
Previous filing: 05 Nov 2025
SEC: View on sec.gov

Reporting Owners (3)

Name	Relationship	Address	Signature	Signature date	CIK
Pivotal bioVenture Partners Fund I, L.P.	Director, 10%+ Owner	501 SECOND STREET, SUITE 200, SAN FRANCISCO	/s/ Robert Hopfner - for Pivotal bioVenture Partners Fund I, L.P., By: Robert Hopfner, Managing Partner	12 Nov 2025	0001695076
Pivotal bioVenture Partners Fund I G.P., L.P.	Director, 10%+ Owner	501 SECOND STREET, SUITE 200, SAN FRANCISCO	/s/ Robert Hopfner - for Pivotal bioVenture Partners Fund I G.P., L.P., By: Robert Hopfner, Managing Partner	12 Nov 2025	0001752862
Pivotal bioVenture Partners Fund I U.G.P. Ltd	Director, 10%+ Owner	501 SECOND STREET, SUITE 200, SAN FRANCISCO	/s/ Robert Hopfner - for Pivotal bioVenture Partners Fund I U.G.P. Ltd., By: Robert Hopfner, Managing Partner	12 Nov 2025	0001752847

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EVMN	Common Stock	Conversion of derivative security		+1,441,032			1,441,032	07 Nov 2025	See footnotes	F1, F2, F3, F4, F5, F10
transaction	EVMN	Common Stock	Conversion of derivative security		+1,632,441			1,632,441	07 Nov 2025	See footnotes	F1, F2, F3, F4, F6, F8, F9
transaction	EVMN	Common Stock	Conversion of derivative security		+294,502			294,502	07 Nov 2025	See footnotes	F4, F7, F8, F9

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EVMN	Series Seed Preferred Stock	Conversion of derivative security		-7,145,647	-100%		0	07 Nov 2025	Common Stock	838,886		See footnotes	F1, F5, F10
transaction	EVMN	Series Seed Preferred Stock	Conversion of derivative security		-3,572,816	-100%		0	07 Nov 2025	Common Stock	419,441		See footnotes	F1, F6, F8, F9
transaction	EVMN	Series A Preferred Stock	Conversion of derivative security		-2,582,243	-100%		0	07 Nov 2025	Common Stock	324,578		See footnotes	F2, F5, F10
transaction	EVMN	Series A Preferred Stock	Conversion of derivative security		-7,230,283	-100%		0	07 Nov 2025	Common Stock	908,821		See footnotes	F2, F6, F8, F9
transaction	EVMN	Series B Preferred Stock	Conversion of derivative security		-1,895,260	-100%		0	07 Nov 2025	Common Stock	240,756		See footnotes	F3, F5, F10
transaction	EVMN	Series B Preferred Stock	Conversion of derivative security		-2,104,740	-100%		0	07 Nov 2025	Common Stock	267,367		See footnotes	F3, F6, F8, F9
transaction	EVMN	Series C Preferred Stock	Conversion of derivative security		-313,571	-100%		0	07 Nov 2025	Common Stock	36,812		See footnotes	F4, F5, F10
transaction	EVMN	Series C Preferred Stock	Conversion of derivative security		-313,571	-100%		0	07 Nov 2025	Common Stock	36,812		See footnotes	F4, F6, F8, F9
transaction	EVMN	Series C Preferred Stock	Conversion of derivative security		-2,508,575	-100%		0	07 Nov 2025	Common Stock	294,502		See footnotes	F4, F7, F8, F9

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series Seed Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration on a 1-for-8.518 basis and had no expiration date.
F2	Each share of Series A Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.9557 basis and had no expiration date.
F3	Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-7.8721 basis and had no expiration date.
F4	Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's IPO for no additional consideration on a 1-for-8.518 basis and had no expiration date.
F5	Held directly by NFLS Delta III Limited ("NFLS Delta"). NFLS Delta is a wholly owned, indirect subsidiary of Nan Fung Group Holdings Limited ("NFGHL").
F6	Held directly by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal I").
F7	Held directly by Pivotal bioVenture Partners Fund II, L.P. ("Pivotal II").
F8	The general partner of Pivotal I is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP I") and the general partner of Pivotal II is Pivotal bioVenture Partners Fund II G.P. Ltd ("Pivotal GP II"). The general partner of Pivotal GP I is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner"). The Ultimate General Partner and Pivotal GP II are each wholly owned by Pivotal Partners Ltd ("Pivotal Partners"). Pivotal Partners is wholly owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings Limited ("NFIHL"), which is wholly owned by NFGHL. Dr. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer.
F9	The members of the Investment Committees of Pivotal GP I and Pivotal GP II make investment decisions with respect to the securities of the Issuer held by Pivotal I and Pivotal II. Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Investment Committees of Pivotal GP I and Pivotal GP II. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein.
F10	The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by NFLS Delta. Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and Dr. Robert Hopfner are the members of the Executive Committee of NFGHL. Such persons and entities disclaim beneficial ownership of these securities except to the extent of their or its proportionate pecuniary interest therein.